Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study | Zendy

Claire Falandry | Zendy; Béatrice Horard | Zendy; Amandine Bruyas | Zendy; Éric Legouffe | Zendy; Jacques Cretin | Zendy; Jérôme Meunier | Zendy; Jérôme Alexandre | Zendy; Valérie Delecroix | Zendy; Michel Fabbro | Zendy; Marie-Noëlle Certain | Zendy; Raymonde Maraval-Gaget | Zendy; Éric Pujade-Lauraine | Zendy; Éric Gilson | Zendy; Gilles Freyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study

Author(s) -

Claire Falandry,

Béatrice Horard,

Amandine Bruyas,

Éric Legouffe,

Jacques Cretin,

Jérôme Meunier,

Jérôme Alexandre,

Valérie Delecroix,

Michel Fabbro,

Marie-Noëlle Certain,

Raymonde Maraval-Gaget,

Éric Pujade-Lauraine,

Éric Gilson,

Gilles Freyer

Publication year - 2015

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.100840

Subject(s) - telomere , ovarian cancer , biomarker , oncology , gerontology , medicine , cancer , gynecology , biology , genetics , dna

Age induces a progressive decline in functional reserve and impacts cancer treatments. Telomere attrition leads to tissue senescence. We tested the hypothesis that telomere length (TL) could predict patient vulnerability and outcome with cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research